Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$73.43 USD

73.43
684,127

+0.80 (1.10%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 24.44% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Globus Medical (GMED) Could Beat Earnings Estimates Again

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.

Trina Mukherjee headshot

Medical Products' Aug 4 Earnings Roster: MCK, ABC & More

The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up

NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?

Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View

Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.

Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up

Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.

Here is Why Growth Investors Should Buy Globus Medical (GMED) Now

Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Globus Medical (GMED) Hits 52-Week High, Can the Run Continue?

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Invest In Globus Medical (GMED) Now

Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.

Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS

Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.

Globus Medical (GMED) Hits New 52-Week High: What's Driving It?

Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.

Why Is Globus Medical (GMED) Down 3.8% Since Last Earnings Report?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise

Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.

Globus Medical (GMED) Moves 5.4% Higher: Will This Strength Last?

Globus Medical (GMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.